Targeting ferroptosis to treat colorectal cancer |
| |
| Institution: | 1. Department of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, CT 06510, USA;2. Department of Pathology, Yale School of Medicine, New Haven, CT, USA;1. Institute of Molecular Medicine, Beijing Key Laboratory of Cardiometabolic Molecular Medicine, College of Future Technology, Peking University, Beijing 100871, China;2. Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China;1. Department of Biological Sciences, Indian Institute of Science Education and Research, Mohali, Punjab 140306, India;1. The Third Affiliated Hospital of Southern Medical University, Department of General Surgery, Guangzhou, China;2. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China;3. Guangzhou Medical University, Guangzhou Women and Children''s Medical Center, Department of Hematology and Oncology, Guangzhou, China;4. Foshan Women and Children Hospital Affiliated to Southern Medical University, Departments of Obstetrics and Gynecology, Foshan, China;5. Hainan Affiliated Hospital of Hainan Medical University, Department of Radiation Oncology, Haikou, China;1. Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;2. Division of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada;1. Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT, United States;2. Yale University School of Medicine, New Haven, CT, United States;3. Yale Center for Perinatal, Pediatric, and Environmental Epidemiology, Yale School of Public Health, New Haven, CT, United States;4. Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, United States;5. Division of Surgical Oncology, Department of Surgery, Yale University School of Medicine, New Haven, CT, United States |
| |
| Abstract: | Ferroptosis has emerged as a promising target for colorectal cancer (CRC) treatment. Although disrupting glutathione metabolism is the primary strategy for ferroptosis induction, additional key pathways link ferroptosis to CRC pathogenesis. Here, we discuss arachidonic acid (AA), energy metabolism, AMP-activated protein kinase (AMPK), phosphatidylinositol-3-kinase (PI3K)-protein kinase B (Akt)-mammalian target of rapamycin (mTOR), and Hippo signaling, summarize key findings, and propose new conceptual avenues for CRC treatment. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
